ArticleAJPM focus2025
Supporting Access to HIV Pre-Exposure Prophylaxis in a Shifting Financial and Insurance Landscape.
Article in AJPM focus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evolving landscape of economic evaluations of HIV pre-exposure prophylaxis and pre-exposure prophylaxis implementation strategies: a systematic review.Journal of the International AIDS Society · 2025Pooled it
- Modelling the 5-Year Impact of Twice-Yearly Injectable Lenacapavir for HIV Pre-Exposure Prophylaxis in the United States.Journal of the International AIDS Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Introduction: Implementing HIV pre-exposure prophylaxis in the U.S. is critical to decreasing HIV transmission. However, regional disparities in pre-exposure prophylaxis use exist, with the southern U.S. having the lowest uptake relative to need. Community-based organizations in the South provide pre-exposure prophylaxis to many consumers, including those without health insurance. Methods: The authors convened a community-building pre-exposure prophylaxis summit in April 2023 with representatives from diverse pre-exposure prophylaxis providers, including community-based organizations in Dallas, Texas, to evaluate the impact of recent changes in pre-exposure prophylaxis funding mechanisms on their capabilities to provide pre-exposure prophylaxis. Participants completed surveys ( Results: The authors found that reduced reimbursements from pre-exposure prophylaxis manufacturers have significantly altered the financial health of community-based organizations in Dallas, Texas, and jeopardized their capacity to provide pre-exposure prophylaxis. Community-based organizations reported difficulty in sustainably providing pre-exposure prophylaxis to uninsured clients because of fewer funds to cover unreimbursed costs for pre-exposure prophylaxis care. Many community-based organizations have diverted resources away from client outreach for pre-exposure prophylaxis and toward helping clients to enroll in commercial insurance plans that cover pre-exposure prophylaxis. These changes have further stressed community-based organizations by increasing the time spent by staff on managing prior authorizations for pre-exposure prophylaxis. Despite finding some success with workarounds, community-based organizations described continued financial fragility. Conclusions: These findings suggest that fragmented funding streams jeopardize the ability of these vital organizations to continue providing pre-exposure prophylaxis services in a jurisdiction with high HIV incidence. Potential solutions include enhanced collaboration across community-based organizations and stable financial support from a national pre-exposure prophylaxis program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.